Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

NCT02291861 is registered in ClinicalTrials.gov with Auspex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02291861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02291861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Lead sponsor
Auspex Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
August 19, 2016
Enrollment
298 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

tardive dyskinesia